Globally, the stem cell therapy market is expected to be worth $40 billion by 2020 and $180 billion by 2030. The largest number of marketed cell therapy products is used for the treatment of notably non-healing wounds/skin (46%) and muscular-skeletal injuries (35%). This trend will change as more and stem cell therapy products for cancer and heart disease complete their clinical trials and are approved for market release.

Adult stem cell leads the market due to low contamination during sub-culture and expansion, relatively low labour production and compatibility with the human body.Just the Induced pluripotent stem cells (IPScs) are expected to report revenue of over USD 4.5 billion by 2020, on account of the analogous nature of its origin.With the continued growth of medical tourism hubs like India, Singapore, and Thailand, Asia is expected to maintain its place as the epicentre of stem cell research and therapy. These opportunities include contract research outsourcing and rising patient population with neurological and other chronic conditions in the region. Japan, Singapore and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming years.

Continued here:
Cell Therapy World Asia - IMAPAC - Imagine your Impact